ERBB2 and breast carcinoma: As mentioned before, the use of these type of molecules have been historically associated to an elevated risk of autoimmunity, but many of them have already been successfully implemented in cancer therapies with minimal adverse effects, such as the molecules MUC1 for epithelial tumors [42] or the human epidermal growth factor receptor 2 (HER2) in breast cancer [43] among many others.